Browsing by Author "Guzel, Baris Can"

Now showing 1 - 3 of 3

Citation - WoS: 14
Citation - Scopus: 13
Regulation of Stat3 and Nf-Κb Signaling Pathways By Trans-anethole in Testicular Ischemia-Reperfusion Injury and Its Gonadoprotective Effect
(Mre Press, 2024) Seker, Ugur; Gokce, Yasin; Kati, Bulent; Yuksel, Meral; Guzel, Baris Can; Shokoohi, Majid
Testicular ischemia reperfusion (I/R) injury is a significant urological problem where clinical interventions may be inadequate, and the antioxidants might be potential co-treatment modalities. This study examined the gonadoprotective effect of trans-Anethole in testicular I/R injury. Twenty-eight male rats were divided into four groups. Rats in the I/R, I/R + t100, I/R + t200 groups underwent bilateral testicular I/R injury. The I/R + t100 and I/R + t200 groups received 100 or 200 mg/kg trans-Anethole at the 2nd hour of ischemia. Microscopic evaluations demonstrated that testicular I/R injury leads to severe testicular degeneration. Tissue oxidative stress, pro-apoptotic Bcl-2 associated X (Bax) and Caspase 3, pro-inflammatory Tumor necrosis factor-alpha (TNF-alpha), Interleukin-1 beta (IL-1 beta) and Interleukin 6 (IL-6) cytokines levels were significantly (p < 0.05) upregulated when compared to the Control group. Additionally, transcription factors Signal transducer and activator of transcription 3 (STAT3) and Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappa B) levels increased significantly (p < 0.05) compared to the Control group. Tissue disrupted parameters in the I/R + t200 group were significantly different (p < 0.05) from the I/R group, contrasting with the slight improvement in the I/R + t100 group. The STAT3 and NF-kappa B expression levels in the I/R + t200 group were significantly suppressed (p < 0.05) compared to the I/R group. In conclusion, our study indicates that trans-Anethole could enhance gonadoprotective activity in testicular I/R injury, potentially involving transcription factors STAT3 and NF-kappa B. However, before the consumption of trans-Anethole-containing natural or manufactured goods, the potential benefits and side effects should be carefully evaluated.
Citation - WoS: 1
Neuroprotective Potential of a Novel Soluble Guanylate Cyclase Stimulator the Riociguat Alone or in a Combination Manner With Resveratrol in Experimental Stroke Model in Rats
(Soc Chilena Anatomia, 2024) Aslanoglu, Baris; Kaya, Seval; Gunara, Sezer Onur; Atlas, Burak; Seker, Ugur; Guzel, Baris Can; Turan, Yahya
In this study we aimed to examine the effect of novel vasodilatory drug Riociguat co-administration along resveratrol to recover neurodegeneration in experimental stroke injury. For that purpose, thirty-five adult female rats were divided into groups five (Control, MCAO, MCAO + R, MCAO + BAY, MCAO + C) of seven animals in each. Animals in Control group did not expose to any application during the experiment and sacrificed at the end of the study. Rats in the rest groups exposed to middle cerebral artery occlusionO) (MCAinduced ischemic stroke. MCAO + R group received 30 mg/kg resveratrol, and MCAO + BAY group received 10 mg/kg Riociguat. The MCAO + C group received both drugs simultaneously. The drugs were administered just before the reperfusion, and the additional e doses weradministered 24h, and 48h hours of reperfusion. All animals in this study were sacrificed at the 72nd hour of experiment. Total brainsreceived were for analysis. Results of this experiment indicated that MCAO led to severe injury in cerebral structure. Bax, IL-6 and IL-1 ss levelstissue were upregulated, but anti-apoptotic Bcl-2 immunoexpression was suppressed (p<0.05). In resveratrol and Riociguat treated animals, the neurodegenerations and apoptosis and inflammation associated protein expressions were improved compared to MCAO group, mosbut the success was obtained in combined treatment exposed animals in MCAO + C group. This study indicated that the novel solubleate guany cyclase stimulator Riociguat is not only a potent neuroprotective drug in MCAO induced stroke, but also synergistic administratio of Riociguat along with resveratrol have potential to increase the neuroprotective effect of resveratrol in experimental cerebral strokeosed rats.
Ectoine-Loaded Solid Lipid Nanoparticles Enhance the Protection of Lacrimal Glands and Corneal Tissues in Dry Eye Disease Through Modulating NF-κB Mediated Signaling Pathway
(Elsevier, 2026) Toksoy, Mahmut Ozan; Seker, Ugur; Guzel, Baris Can
Dry eye disease (DED) is a multifactorial disorder associated with tear film instability, inflammation, and ocular surface damage. This study aimed to develop and evaluate Ectoine-loaded solid lipid nanoparticles (Ect-SLNs) as a novel ocular drug delivery system to improve corneal penetration, retention, and therapeutic efficacy. Ect-SLNs were formulated using a Box-Behnken design and characterized for particle size, polydispersity index, zeta potential, and encapsulation efficiency. In vitro release kinetics were assessed. Ex vivo ocular retention studies were performed using bovine cornea. In vivo therapeutic efficacy was evaluated in a scopolamine-induced rat model of DED, with histological and immunohistochemical analyses of corneal and lacrimal gland tissues. The optimized Ect-SLN formulation exhibited a mean particle size, zeta potential and entrapment efficiency of 241.3 +/- 32.1 nm, -15.76 +/- -4.14 mV, and 32.84 + 3.15 % respectively. In vitro studies demonstrated that Ect-SLNs showed sustained release following Higuchi kinetics (r(2) = 0.991). Ex vivo studies confirmed 1.6-fold higher corneal retention compared to Ectoine solution. Animal studies showed that Ect-SLNs significantly improved glandular and corneal morphology, epithelial keratinization, apoptotic (Bax, Caspase-3) and pro-inflammatory (TNF-alpha, IL-1 beta) markers through NF-kappa B signaling pathway (p < 0.05). In addition, Ect-SLN formulation significantly inhibited the upregulated EGFR in corneal tissue, which is an important hallmark of neovascularization (p < 0.05). Ect-SLNs provided superior therapeutic benefits over conventional Ectoine solution by enhancing bioavailability, prolonging ocular residence, and modulating inflammatory and apoptotic responses. These findings suggest that Ect-SLNs constitute a promising nanocarrier platform for the clinical management of dry eye disease.